Skip to content
Back to explorer
Printable monograph

PARP inhibitor

Talazoparib

Talzenna · Tala

PARP inhibitor · approved 2018 · 6 citations

Up to date· through 2026
Fairly sourced5/9 · 5 signals
  • Met: 6 citations
  • Not met: 12+ references
  • Not met: Accrued over 10+ years (span: 8y)
  • Met: Beyond single case reports
  • Met: High-impact journal
  • Met: Landmark reference
  • Met: Current through 2026
  • Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A potent, renally cleared PARP-trapper — renal impairment raises exposure and dosing must adjust.

MildPARP inhibitor
gBRCA-mutated HER2-negative breast cancerMetastatic castration-resistant prostate cancer (with enzalutamide)

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Reduce dose by kidney function
CrCl 60-89 no change; CrCl 30-59 reduce to 0.75 mg daily; CrCl 15-29 reduce to 0.5 mg daily; not studied <15/dialysis
The atlas summary, paraphrased — not label text. Verbatim label excerpt. Dosing section.
Hemodialysis
Unknown
Use restricted: Not studied on dialysis or CrCl<15; avoid or use only with intensive hematologic monitoring
Renally cleared but highly protein-bound with dialyzability not formally established; avoid on dialysis (not studied in CrCl<15) or use only with intensive hematologic monitoring, while lesser renal impairment warrants dose reduction.PMID 33686631 (opens PubMed in a new tab)
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
None on the excerpted label
Label: Talzenna, Oct 2026. FDA label section.
Pseudo-AKI
Documented to raise creatinine by blocking its tubular secretion — an isolated creatinine rise on this agent may be pseudo-AKI, not true injury. Confirm with a cystatin-C-based or measured GFR before holding therapy.
Pseudo-AKI in the injury atlas.
§01

Signature kidney injury

Signature lesion

Renal clearance is a major elimination route (~two-thirds of dose), so exposure rises with declining renal function: dedicated PK studies show higher AUC and more myelosuppression in moderate-severe impairment, mandating dose reduction. Class-level mild creatinine elevation may occur; severe intrinsic nephrotoxicity is uncommon.Source: Durairaj et al., Clin Pharmacokinet 2021

Onset & rechallenge

Time to injuryVariable / unpredictable

The pharmacokinetic effect is present from initiation in patients with reduced renal function, while cytopenias accrue over the first cycles.

Distilled from: “The pharmacokinetic effect is present from initiation in patients with reduced renal function; cytopenias accrue over the first cycles.”

§02

Renal toxicities, ranked

This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

  1. Pseudo-AKI#1 · Signaturequalitative — no citable incidence

    The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.

§03

Kidney injury

Mechanism of kidney injury

Talazoparib is substantially renally cleared, so reduced GFR increases drug exposure (and hematologic toxicity) rather than causing direct tubular injury — the dominant renal issue is pharmacokinetic. As with the class, any modest creatinine rise can reflect inhibition of tubular creatinine secretion rather than true filtration loss.

Clinical presentation

Usually no overt nephrotoxicity; the renal concern is pharmacokinetic — higher exposure with anemia, thrombocytopenia, and neutropenia in patients with reduced renal function. Mild reversible creatinine changes are possible.

Management

Reduce the starting dose for moderate (CrCl 30-59: 0.75 mg daily) and severe (CrCl 15-29: 0.5 mg daily) renal impairment per label; manage cytopenias with dose holds/reductions, transfusion, and growth-factor support.Lesion-level management framework

Risk factors

  • Moderate to severe renal impairment (exposure)
  • Concurrent myelosuppressive therapy
  • Concurrent P-gp/BCRP inhibitors

Prevention

  • Renal-function-based starting-dose adjustment
Anticancer mechanism· how it treats cancer

One of the most potent PARP-trapping inhibitors; exploits homologous-recombination deficiency for synthetic lethality. Used in germline BRCA-mutated HER2-negative breast cancer and, with enzalutamide, in metastatic castration-resistant prostate cancer.

§04

Clinical depth

Renal dose adjustment

Breast-cancer monotherapy: CrCl 60-89 no change; CrCl 30-59 reduce to 0.75 mg once daily; CrCl 15-29 reduce to 0.5 mg once daily. With enzalutamide in mCRPC, label-specific lower doses apply. Not studied on dialysis or in CrCl <15 mL/min.

Dialyzability & ESKD dosing

Renally cleared but highly protein-bound; dialyzability not formally established and no validated ESKD dose — avoid or use only with intensive hematologic monitoring.

Differential diagnosis

Cytopenias in a CKD patient on talazoparib usually reflect drug over-exposure (PK), not marrow infiltration or a separate renal lesion. A mild creatinine rise is more likely transporter-mediated than true AKI.

Monitoring

  • CBC monthly (and more often after dose changes) — anemia is the most common grade >=3 event
  • Blood counts more closely in CKD

Key trials & series

  • EMBRACA (gBRCA HER2-negative breast cancer)
  • TALAPRO-2 (talazoparib + enzalutamide in mCRPC)
  • Durairaj 2021 dedicated renal-impairment PK study

Clinical pearls

  • Talazoparib is the renally cleared PARP inhibitor — reduce the dose for CrCl <60 mL/min and watch counts, since exposure (and anemia) climbs as GFR falls.
  • The principal renal issue is dosing in CKD, not de novo kidney injury.
  • Confirm an ambiguous creatinine rise with cystatin C before attributing GFR decline.
Where it strikes· nephron segments & injury signatures

Nephron segments

Proximal Tubule

Bulk reabsorption + drug uptake (OCT2, OATs)

Vasculature / Endothelium

Glomerular & peritubular capillaries

Injury signatures

§05

References

6 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

6 references · 2018–2026 · 2 since 2024
102018: 1 citation2019: 1 citation2021: 1 citation2022: 1 citation2024: 1 citation2026: 1 citation201820202026

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

  1. 1.LandmarkThe Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors.Durairaj C et al. · Clin Pharmacokinet · 2021 · PMID 33686631Dedicated PK study showing increased talazoparib exposure with renal impairment, supporting dose adjustment.
  2. 2.Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer.Yu Y et al. · J Clin Pharmacol · 2019 · PMID 31489639Population PK identifying renal function as a covariate on talazoparib clearance.
  3. 3.PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Gasowska-Bodnar A et al. · Cancers (Basel) · 2026 · PMID 42073552Class-level evidence that PARP-inhibitor creatinine rise is usually mild and transporter-mediated.
  4. 4.Exploring and comparing renal adverse effects between PARP inhibitors based on a real-world analysis of post-marketing surveillance data.Xu Q et al. · Front Med (Lausanne) · 2024 · PMID 39493722Real-world renal adverse-event comparison across PARP inhibitors, contextualizing talazoparib safety.
  5. 5.Targeted Cancer Therapies Causing Elevations in Serum Creatinine Through Tubular Secretion Inhibition: A Case Report and Review of the Literature.Mach T et al. · Can J Kidney Health Dis · 2022 · PMID 35756332Frames cystatin C as the confirmatory test for targeted-therapy creatinine elevation.
  6. 6.Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.Litton JK et al. · N Engl J Med · 2018 · PMID 30110579Pivotal EMBRACA trial: registrational efficacy/safety dataset (anemia-dominant hematologic toxicity relevant to CKD dosing).
FDA label — boxed warning & renal dosing· renal impairment

Quoted verbatim from this agent's current FDA label (Oct 2026) — not paraphrased or interpreted. Full label on DailyMed .

Renal impairment — from the label

Reduce the recommended dosage of TALZENNA in patients with moderate (CLcr 30 – 59 mL/min) and severe (CLcr 15 – 29 mL/min) renal impairment [see Dosage and Administration (2.6) ] . Monitor patients with severe renal impairment for increased adverse reactions and modify the dosage as recommended for adverse reactions [see Dosage and Administration (2.5) ] . No dose adjustment is recommended for patients with mild renal impairment (CLcr 60 – 89 mL/min). TALZENNA has not been studied in patients requiring hemodialysis.

Kidney rows of the label's dosage tables

From the Talzenna label (Oct 2026) · DailyMed

No row of this label's 3 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 1,853 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

  • Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
  • Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
  • Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.
FAERS reported renal phenotypes· 3 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.

What reporting says about this profile's documented lesions

  • Pseudo-AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
SIADH / Hyponatremia
ROR 2.4595% CI 1.56–3.84· 19 reports· IC025 0.51
Hemorrhagic Cystitis
ROR 2.0195% CI 1.16–3.46· 13 reports· IC025 0.06
Electrolyte Disturbance
ROR 1.8995% CI 1.35–2.64· 35 reports· IC025 0.37
FAERS outcomes & reporting trend· 18.5% of reports w/ death · 34.1% w/ hospitalization
18.5%

Reported with a death outcome

342 of 1,853 reports

34.1%

Reported with hospitalization

632 of 1,853 reports

Reports per year

  • 2015: 5 reports
  • 2016: 2 reports
  • 2017: 21 reports
  • 2018: 29 reports
  • 2019: 210 reports
  • 2020: 202 reports
  • 2021: 154 reports
  • 2022: 199 reports
  • 2023: 252 reports
  • 2024: 239 reports
  • 2025: 336 reports
  • 2026: 204 reports

Reports received per year, 2015–2026 · most recent year is partial.

FAERS adverse-event signal — all organ systems· 7 systems · 1,853 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.

Disproportionality (acute kidney injury):ROR 0.6195% CI 0.35–1.08· 12 AKI reports· IC025 −1.61·no disproportionate AKI reporting signal (CI spans 1).
Blood & lymphatic
Anaemia285Thrombocytopenia100Haemoglobin Decreased85Platelet Count Decreased79Febrile Neutropenia71
General / constitutional
Fatigue137Asthenia63Pyrexia34Malaise31
Gastrointestinal
Nausea67Diarrhoea36Vomiting30
Respiratory
Dyspnoea50
Nervous system
Dizziness41
Immune / infection
Pneumonia40
Metabolic & electrolyte
Decreased Appetite34
Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Talazoparib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.
Phenotype-similar agents· the numbered markers on the map above

Rucaparib

Rubraca · PARP inhibitor

Profile

Transporter-mediated creatinine rise.

PSEUDO
Mild#1 · 100% phenotype match

Niraparib

Zejula · PARP inhibitor

Profile

Hypertension and creatinine rise.

HTNPSEUDO
Mild#2 · 76% phenotype match

Olaparib

Lynparza · PARP inhibitor

Profile

Benign creatinine rise via OCT2/MATE inhibition.

PSEUDOTMA
Mild#3 · 76% phenotype match

Larotrectinib

Vitrakvi · TRK inhibitor

Profile

Mild creatinine rise; generally well tolerated.

PSEUDO
Mild#4 · 75% phenotype match

Entrectinib

Rozlytrek · TRK/ROS1 TKI

Profile

Creatinine rise via reduced tubular secretion.

PSEUDO
Mild#5 · 75% phenotype match

Tucatinib

Tukysa · HER2 TKI

Profile

Benign creatinine rise via tubular secretion inhibition.

PSEUDO
Mild#6 · 75% phenotype match
Compare Talazoparib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across PARP inhibitor agents

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.

  1. 1RucaparibMild
  2. 1Talazoparib· this agentMild
  3. 3NiraparibMild
  4. 3OlaparibMild

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.